Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Dermatologic 3Head & Neck 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1

Conditions

Melanoma 3Skin Neoplasms 1Immune System Diseases 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × pimonidazole × Dermatologic × Clear all
NCT04658303 2025-05-08

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

University of Pittsburgh

Recruiting
20 enrolled
Dermatologic

Immune System Diseases, Melanoma

NCT06831071 2025-05-08

Evaluation of Hypoxia in Primary Melanoma

University of Pittsburgh

Recruiting
50 enrolled
Dermatologic

Melanoma

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡